サインイン

このコンテンツを視聴するには、JoVE 購読が必要です。 サインイン又は無料トライアルを申し込む。

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This protocol describes and compares two representative methods for differentiating hiPSCs into mesenchymal stromal cells (MSCs). The monolayer method is characterized by lower cost, simpler operation, and easier osteogenic differentiation. The embryoid bodies (EBs) method is characterized by lower time consumption.

Abstract

Mesenchymal stromal cells (MSCs) are adult pluripotent stem cells which have been widely used in regenerative medicine. As somatic tissue-derived MSCs are restricted by limited donation, quality variations, and biosafety, the past 10 years have seen a great rise in efforts to generate MSCs from human induced pluripotent stem cells (hiPSCs). Past and recent efforts in the differentiation of hiPSCs into MSCs have been centered around two culture methodologies: (1) the formation of embryoid bodies (EBs) and (2) the use of monolayer culture. This protocol describes these two representative methods in deriving MSC from hiPSCs. Each method presents its advantages and disadvantages, including time, cost, cell proliferation ability, the expression of MSC markers, and their capability of differentiation in vitro. This protocol demonstrates that both methods can derive mature and functional MSCs from hiPSCs. The monolayer method is characterized by lower cost, simpler operation, and easier osteogenic differentiation, while the EB method is characterized by lower time consumption.

Introduction

Mesenchymal stromal cells (MSCs) are mesoderm-derived adult pluripotent stem cells1. MSCs are present in almost all connective tissues2. Since MSCs were first discovered in the 1970s and successfully isolated from bone marrow in 1987 by Friedenstein et al.3,4,5, a variety of human somatic (including fetal and adult) tissues have been used for isolating MSCs such as bone, cartilage, tendon, muscle, adipose tissue, and hematopoietic-supporting stroma1,2,

Protocol

1. hiPSCs maintenance

  1. Thawing of hiPSC
    1. Take out the cells from the liquid nitrogen and quickly thaw cells in a 37 °C water bath. Transfer the thawing cells to a 15 mL tube prepared with 3 mL of iPSC maintenance medium (Table of Materials). Gently mix the medium.
    2. Centrifuge at 300 x g for 5 min. Remove the supernatant, and gently resuspend the cells in 1 mL of iPSC maintenance medium with 10 µM Y-27632 (pipette the cells up and down 2-.......

Representative Results

Following the protocol (Figure 1A), hiPSCs were differentiated into MSCs via the EB formation and monolayer culture methods. During differentiation, the cells showed different representative morphologies (Figure 1B,C).

As shown in Figure 1B, the hiPSCs colonies display typical compact morphology before differentiation with a clear border composed of tightly packed cells. Uniform spherical.......

Discussion

In this protocol, two representative methods of differentiating hiPSCs into MSCs were examined20,21,22,23,24,25,26,27,28,30. Both methods were capable of derivating MSCs from hiPSCs. The .......

Acknowledgements

We are extremely grateful to all members of the Mao and Hu Lab, past and present, for the interesting discussions and great contributions to the project. We are thankful to the National Clinical Research Center for Child Health for the great support. This study was financially supported by the National Natural Science Foundation of China (U20A20351 to Jianhua Mao, 82200784 to Lidan Hu), the Natural Science Foundation of Zhejiang Province of China (No. LQ22C070004 to Lidan Hu).

....

Materials

NameCompanyCatalog NumberComments
Alizarin red staining kitBeyotime BiotechnologyC0148S
Anti-human-CD105 (PE)Biolegend323206
Anti-human-CD34 (FITC)Biolegend343503
Anti-human-CD45 (APC)Biolegend304011
Anti-human-CD73( APC)Biolegend344006
Anti-human-CD90 (FITC)Biolegend328108
Ascorbic acidSolarbioA8100
BMP-6NovoproteinC012
Carbon dioxide level shakerCrystalCO-06UC6
Compensation BeadsBioLegend424601
CryoStor CS10STEMCELL Technology07959
DexamethasoneBeyotime BiotechnologyST1254
DMEM/F12  mediumServicebioG4610
Fetal bovine serumHAKATAHS-FBS-500
FGF2Stemcell78003.1
GelatinSigma-AldrichG2500-100G
GlutaMAXGibco35050061
human IgG1 isotype control APCBioLegend403505
human IgG1 isotype control FITCBioLegend403507
human IgG1 isotype control PEBioLegend403503
Human TGF-β1Stemcell78067
Human TruStain FcX BioLegend422301
IBMXBeyotime BiotechnologyST1398
IndomethacinSolarbioSI9020
InsulinBeyotime BiotechnologyP3376
iPSC maintenance mediumSTEMCELL Technology85850
ITS Media SupplementBeyotime BiotechnologyC0341-10mL
Matrigel, growth factor reducedBD Corning354230
Oli Red O staining kitBeyotime BiotechnologyC0158S
ProlineSolarbioP0011
Sodium pyruvateThermoFisher11360-070
TGFβ3NovoproteinCJ44
Toluidine blue staining kitSolarbioG2543
TrypLE Express Enzyme(1x) Gibco12604013
Ultra-Low Attachment 6 Well PlateCostar3471
VerseneGibco15040-66
Y-27632Stemcell72304
α-MEMHycloneSH30265
β-glycerophosphateSolarbioG8100

References

  1. Weng, Z., et al. Mesenchymal stem/stromal cell senescence: Hallmarks, mechanisms, and combating strategies. Stem Cells Translational Medicine. 11 (4), 356-371 (2022).
  2. Soliman, H., et al. Multipotent stromal....

Explore More Articles

Induced Pluripotent Stem CellsMesenchymal Stromal CellsDifferentiationEmbryoid BodiesMonolayer CultureRegenerative MedicineDisease ModelingPatient derived Cells

This article has been published

Video Coming Soon

JoVE Logo

個人情報保護方針

利用規約

一般データ保護規則

研究

教育

JoVEについて

Copyright © 2023 MyJoVE Corporation. All rights reserved